Company

Surv Biopharma Inc.

Surv Biopharma develops oncolytic virus therapies and provides pharmaceutical development and support services.

About

Founded in Kagoshima in 2022, Surv Biopharma develops oncolytic virus therapies and provides clinical, diagnostic, consulting, manufacturing, and sales support. Its m-CRA platform is designed to target cancer cells, and its Surv.m-CRA series targets survivin. In November 2025, it raised JPY 1.5 billion in Series B funding led by Keio Innovation Initiative, with other new and returning investors participating, to advance non-clinical and international clinical development.

3Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in